Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC

Sovran Advisors LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,619 shares of the biopharmaceutical company’s stock after selling 2,519 shares during the quarter. Sovran Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $6,395,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $226,000. M&T Bank Corp grew its stake in shares of Regeneron Pharmaceuticals by 16.6% in the 2nd quarter. M&T Bank Corp now owns 5,929 shares of the biopharmaceutical company’s stock worth $3,113,000 after purchasing an additional 843 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $3,183,000. Finally, Kennedy Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 5,106 shares of the biopharmaceutical company’s stock worth $2,681,000 after purchasing an additional 90 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $761.85 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The firm has a market capitalization of $80.54 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.02 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company’s 50 day simple moving average is $766.62 and its 200-day simple moving average is $713.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $12.07 EPS. The company’s revenue was up 2.5% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $804.70.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EYLEA HD (aflibercept) received FDA approval with extended dosing intervals up to five months for wAMD and DME — this can raise lifetime patient value, reduce treatment burden, and boost Regeneron’s retina revenue and competitive positioning. EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
• Positive Sentiment: Regeneron struck a strategic collaboration with TriNetX to access ~300 million de‑identified EHR records, giving it broader phenotypic linkage to its genomic/proteomic datasets — this should accelerate target discovery, improve clinical-trial design, and strengthen AI-driven drug development over time. Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
• Positive Sentiment: Analyst commentary and Zacks/Yahoo pieces highlight Regeneron’s strong earnings‑surprise history and factors that point to another potential beat — supporting short‑term investor optimism ahead of upcoming results. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Regeneron told investors it expects to be excluded from the U.S. list facing proposed pharma tariffs — that reduces near‑term policy risk and potential margin pressure relative to peers. Regeneron says it expects to avoid new US pharma tariffs
• Neutral Sentiment: Piper Sandler has initiated coverage of Regeneron (details of the call/rating were not in the summary) — coverage can increase attention/liquidity but the impact depends on the firm’s stated rating and model. Piper Sandler Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Insiders Place Their Bets

In related news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.